A large, randomized trial provides a head-to-head comparison of late complications involving the two approaches to BPH.
Statins may improve outcomes in hormone-sensitive prostate cancer, and one possible mechanism responsible may have been discovered.
The review “represents the best available evidence for the morbidity and cost profile” of robot-assisted versus open radical prostatectomy, says one of the study’s authors.
Focal therapy has been promoted as a minimally morbid option for men with localized low-risk prostate cancer who nevertheless want their disease treated. Opponents of focal therapy note the heterogeneity and multifocal nature of prostate cancer, the difficulty of accurately targeting and destroying an index tumor with focal therapy, and the unknown biologic potential of the tumor.
Higher PSA density at diagnosis is associated with biopsy progression of low-risk prostate cancer in patients enrolled in active surveillance.
Adding local radiotherapy to hormonal treatment more than halves long-term prostate cancer-specific mortality and substantially decreases overall mortality in men with non-metastatic locally advanced or high-risk prostate cancer, according to an updated analysis of clinical trial data from the Scandinavian Prostate Cancer Group’s Study VII.
The investigational 17,20 lyase inhibitor orteronel failed to significantly extend overall survival in an international phase III study of patients with metastatic castration-resistant prostate cancer.
Testosterone replacement therapy (TRT) in hypogonadal men does not appear to increase the risk for prostate cancer, according to an evaluation of 224 men with an indication for prostate biopsy, providing further evidence that TRT need not be avoided in this patient group.
A new generation of prostate cancer biomarkers promises to alter the way in which urologists make clinical management decisions.
No differences in body composition were found among metastatic castration-resistant prostate cancer patients taking abiraterone acetate (ZYTIGA), enzalutamide (Xtandi), or placebo who were treated as part of two clinical trials.